AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...

Stem cell therapy has emerged as a groundbreaking treatment option for corneal injuries, offering hope to individuals suffering from severe damage to the cornea.Cornea is the transparent, dome-shaped ...

Optimal therapeutic targeting of cancer involves clonal signals which are expressed within all cancer cellsGradalis applies a novel clinically ...

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in ...

The global autologous cell therapy market, valued at USD 10.12 billion in 2024, is poised for remarkable expansion, reaching a projected valuation of USD 44.55 billion by 2033. This growth, driven by ...

A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...

USA: A clinical study has demonstrated that transplanted autologous corneal stem cells effectively repaired irreversible ...

Results from a phase 1/2 clinical trial of a novel stem cell treatment for cornea injuries found 14 patients treated and tracked for 18 months had a more than 90% success rate at restoring the ...

Based on its cash, cash equivalents and investments as of December 31, the company continues to expect its cash runway to fund operations into ...

Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...

A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem ...